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Autoimmune reactions involving cytochrome P4502E1 (CYP2E1) are a feature of idiosyncratic liver injury
induced by halogenated hydrocarbons and isoniazid, but are also detectable in about one third of the
patients with advanced alcoholic liver disease (ALD) and chronic hepatitis C (CHC). In these latter the
presence of anti-CYP2E1 auto-antibodies is an independent predictor of extensive necro-inﬂammation
and ﬁbrosis and worsens the recurrence of hepatitis following liver transplantation, indicating that
CYP2E1-directed autoimmunity can contribute to hepatic injury. The molecular characterization of the
antigens recognized by anti-CYP2E1 auto-antibodies in ALD and CHC has shown that the targeted con-
formational epitopes are located in close proximity on the molecular surface. Furthermore, these epi-
topes can be recognized on CYP2E1 expressed on hepatocyte plasma membranes where they can trigger
antibody-mediated cytotoxicity. This does not exclude that T cell-mediated responses against CYP2E1
might also be involved in causing hepatocyte damage. CYP2E1 structural modiﬁcations by reactive
metabolites and molecular mimicry represent important factors in the breaking of self-tolerance against
CYP2E1 in, respectively, ALD and CHC. However, genetic or acquired interferences with the mechanisms
controlling the homeostasis of the immune system are also likely to contribute. More studies are needed
to better characterize the impact of anti-CYP2E1 autoimmunity in liver diseases particularly in relation to
the fact that common metabolic alterations such as obesity and diabetes stimulates hepatic CYP2E1
expression.
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).CYPs as targets of auto-immunity
Enzymes are common targets of immune-mediated reactions in
liver autoimmune diseases. In these conditions, the breaking of
self tolerance often involves various cytochrome P450 (CYP) iso-
enzymes [1]. CYPs are a large family of heme-containing proteins
that are involved in the biotransformation of xenobiotics, but are
also responsible for processing endogenous substrates and in theBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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homologies various CYPs are classiﬁed in families and sub-families
identiﬁed by a combination of numbers and letters [2]. The in-
volvement of CYPs as targets in autoimmunity streams from early
reports showing that steroyl-21α hydroxylase (CYP21), cholesterol
side-chain cleavage enzyme (CYP11A) and steroid-17α hydro-
xylase (CYP17) were the major adrenal cortex auto-antigens in
idiopathic Addison's disease [3], while anti-CYP1A1 auto-anti-
bodies are a characteristic of the hepatitis associated with type-1
polyendocrine syndrome [4]. From these observations, subsequent
studies have implicated immunity against hepatic CYPs in idio-
syncratic adverse reactions to drugs and in autoimmune hepatitis.
In particular, antibodies against different CYP isoforms were de-
tected in the case of dihydralazine- (anti-CYP1A2) or tienilic acid-
(anti-CYP2C9) induced hepatitis as well as during hypersensitivity
reactions to the aromatic anti-convulsants (anti-CYP3A) or in
children treated with immunosuppressive drugs (CYP3A4,
CYP2C9) [5–9]. The relevance of these observations in relation to
the pathogenesis of drug-induced hepatitis was supported by the
demonstration of that several functional CYP isoforms are trans-
ported from the Golgi apparatus via the secretory vesicles [10] to
the plasma membrane of hepatocytes, where they and can be
targeted by anti-CYP antibody [11,12].
A further aspect of the involvement of CYP in autoimmune
reactions against the liver concerns anti-liver kidney microsome
type I (LKM-1) antibodies which speciﬁcally target CYP2D6 [1] and
are detectable in type II auto-immune hepatitis and in about 10%
of patients with virus C (HCV) hepatitis [13]. Because of their
prevalence, LKM-1 auto-antibodies have been extensively in-
vestigated showing that they recognize few immune-dominant
epitopes formed by speciﬁc amino acid sequences located on the
surface of the molecule [14–18]. CYP2D6, as other CYP isoenzymes,
reaches the hepatocyte plasma membranes where can be targeted
by circulating LKM-1 antibodies [19]. The clinical relevance of anti-
CYP2D6 auto-reactivity is further supported by the detection of
auto-reactive cytotoxic T-lymphocytes in patients with type-II
autoimmune hepatitis and high titers of anti-CYP2D6 IgG [20,21].
Moreover, mice infection with CYP2D6-expressing Ad5 adenovirus
leads to the production of anti-CYP2D6 IgG that cause immune-
mediated liver injury by recognizing the same epitopes targeted
by human auto-antibodies [22]. It is also noteworthy that beside
CYP2D6, hepatitis C patients show auto-antibodies against other
members of the CYP2 family, particularly CYP2A6 [23,24].Autoimmune reactions targeting CYP2E1
Among the cytochrome P-450 family members, the isoenzyme
2E1 (CYP2E1) has been extensively investigated as it is a key en-
zyme in the metabolic activation of a variety of xenobiotics and
carcinogens, including nitrosamines, benzene, vinyl chloride and
halogenated solvents, and signiﬁcantly contributes to the meta-
bolism of ethanol to acetaldehyde [25]. As others CYPs, the 2E1
isoenzyme is readily inducible by the exposure to xenobiotics and
alcohol consumption, but also by ketone bodies and hypoxia [25].
Furthermore, CYP2E1 has a high NADPH oxidase activity that leads
to the generation of reactive oxygen species (ROS) and sig-
niﬁcantly contributes to the induction of oxidative stress in many
pathological conditions [25]. Within the liver, CYP2E1 is mainly
expressed in the endoplasmic reticulum of centrilobular hepato-
cytes, but two CYP2E1 variants accounting for 30–40% of the mi-
crosomal enzyme activity are also localized in the mitochondrial
matrix (mtCYP2E1s) [25]. Moreover, a small CYP2E1 fraction
(about 10% or the microsomal content) is also expressed on the
outer layer of the hepatocyte plasma membranes [26]. Plasma
membrane CYP2E1 is catalytically active [27], but this latterlocalization is particularly important in relation to auto-immune
reactions.
The involvement of CYP2E1 in liver autoimmunity has emerged
from studies by Bourdi and co-workers [28] and Eliasson and
Kenna [29] who reported that about 70% of the patients suffering
from hepatitis induced by the halogenated anesthetic halothane
develop auto-antibodies speciﬁcally targeting CYP2E1. These auto-
antibodies were identiﬁed as IgG isotype 4 [30]. Anti-CYP2E1 IgG
were also detected in anesthesiologists exposed to halogenated
hydrocarbon anesthetic gases [31], but not in other workers pro-
fessionally exposed to similar gases used in refrigeration industry
[32], in spite these latter may cause liver damage [33]. More re-
cently, CYP2E1 has been recognized together with CYP3A4 and
CYP2C9 as self-antigen in autoimmune reactions developing in
subjects with idiosyncratic liver injury following isoniazid-based
treatment for tuberculosis [34].
As mentioned above, CYP2E1 plays an important role in hepatic
alcohol metabolism. During CYP2E1-mediated ethanol oxidation
ethanol it self is converted to a free radical intermediate, known as
hydroxyethyl free radicals (HER), that by reacting with CYP2E1
generate immunogenic adducts [35]. These anti-HER antibodies
are detectable in the sera of either chronically ethanol-fed rats or
patients with alcoholic liver disease (ALD) where they strictly
correlate with CYP2E1 activity [36,37]. Moreover, human anti-HER
IgG activate antibody-dependent cell-mediated cytotoxicity by
selectively recognizing HER-modiﬁed CYP2E1 on the plasma
membranes of ethanol-treated hepatocytes [38]. By extending
these observations, Lytton and co-workers have reported that
chronic intragastric alcohol-fed rats develop IgG directed towards
CYP2E1 and CYP3A4 and that similar antibodies were also evident
in the sera of alcohol abusers [39]. Interestingly, rats anti-CYP2E1
auto-reactivity correlates with the extent of hepatic injury [39]. In
subsequent studies using a larger cohort of patients we have
conﬁrmed that high titers of anti-CYP2E1 auto-antibodies are
present in about 40% of the subjects with advanced ALD and 11% of
the heavy drinkers with fatty liver only [40]. In the former the
presence of anti-CYP2E1 IgG correlates with the extent of lym-
phocyte inﬁltration and the number of apoptotic hepatocytes in
liver biopsies [41], suggesting a possible contribution of auto-im-
mune mechanisms in the pathogenesis of alcohol liver injury. The
presence of anti-CYP2E1 immunity in ALD is not surprising, as
these subjects frequently have signs of auto- and allo-immune
reactions that are associated with the stimulation of lobular in-
ﬂammation [42,43]. In particular, ALD patients show circulating
anti-phospholipid auto-antibodies as well as IgG targeting pro-
teins modiﬁed by the reaction with acetaldehyde, acetaldehyde/
malondialdehyde (MAA) conjugates and lipid peroxidation end-
products [44–48].
An other liver disease often associated with the presence of
autoimmune responses involving CYP2E1 is chronic hepatitis C
(CHC). Extrahepatic manifestations of autoimmunity are a com-
mon feature of CHC along with the presence of non-organ-speciﬁc
auto-antibodies [14]. Furthermore, as mentioned above anti-
CYP2D6 LKM-1 auto-antibodies are detectable in about 10% of CHC
patients [14]. Using immuno-enzymatic tests we have observed
that 38–40% of CHC patients have anti-CYP2E1 IgG which are
unrelated to LKM-1 antibodies and do not cross-react with
CYP2D6 [49,50]. The presence of these auto-antibodies is in-
dependent from circulating gamma-globulin levels and the viral
genotype, indicating that they represent a general response to HCV
infection [49,50]. It is interesting to note that, in spite both alcohol
and HCV infection promote the development of anti-CYP2E1 au-
toimmunity, in our hands alcohol consumption by CHC patients
did not increase the prevalence of anti-CYP2E1 auto-antibodies
[49,50], suggesting that the breaking of self-tolerance promoted by
alcohol and HCV infection are a rather independent and do not
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auto-antibodies in CHC are associated with a 11 fold increase in
the prevalence of severe necro-inﬂammation (grading Z4 ac-
cording to Ishack's criteria) and 4 fold increased risk of ﬁbrosis.
Moreover, multivariate analysis indicates anti-CYP2E1 IgG as an in-
dependent predictors of severe necro-inﬂammation in hepatitis C
[49,50]. A further aspect of the involvement of anti-CYP2E1 auto-re-
activity in CHC concerns the outcomes of the disease following liver
transplantation. Now days end-stage CHC is becoming the main in-
dication for orthotopic liver transplant (OLT) in Europe and United
States. However, the recurrence of HCV infection in the transplanted
organ is universal and the disease in OLT recipients follows a more
aggressive course [51]. In this context, the development of auto-
immune reactions after OLT is reported with rising frequency [52]. By
investigating OLT recipients before and twelve months after trans-
plantation we have observed that the prevalence of anti-CYP2E1 auto-
antibodies in these patients is not appreciably modiﬁed by the liver
transplant. However, the subjects who have elevated anti-CYP2E1 IgG
before and maintained it after OLT have signiﬁcantly higher incidence
of recurrent hepatitis with severe necro-inﬂammation and ﬁbrosis
than those persistently negative or showing anti-CYP2E1 reactivity
only before or after the transplant [53]. Moreover, the subjects per-
sistently anti-CYP2E1-positive are at high risk of developing severe
liver damage one year after OLT [53], indicating that autoimmune
reactions involving CYP2E1 might contribute to hepatic injury in
transplanted patients with recurrent hepatitis C.Characterization of antigenic epitopes in CYP2E1
The analysis aimed to characterize the epitopes recognized by
anti-CYP2E1 IgG associated with alcohol abuse, drug-inducedFig. 1. Tri-dimensional simulated structure of CYP2E1 showing the localization of the con
with alcoholic liver disease or halothane-induced hepatitis (panels A, B) or chronic hepati
is evidenced in orange and speciﬁc amino acids are stained in purple. (Panel B) The ep
interpretation of the references to color in this ﬁgure legend, the reader is referred to thepatotoxicity and HCV infection have revealed that, in-
dependently from the etiology, these auto-antibodies are mainly
unreactive toward the unfolded molecule, indicating a prevalent
recognition of conformational antigens [54,55]. This make difﬁcult
to identify the speciﬁc epitopes as they can not be investigated by
their cross-reaction with short peptides reproducing the protein
sequence. To overcome such a difﬁculty we have used a metho-
dology based on the combination of computer simulation and the
analysis of the whole molecule antigenic properties following
targeted single amino acid substitutions which do not alter
CYP2E1 correct folding [54]. By this approach we have shown that
anti-CYP2E1 IgG from patients with halothane hepatitis or ALD
preferentially recognized two distinct epitopes on the CYP2E1
surface corresponding to the G-helix (Lys243 -Lys251) and an area
(Lys324 -Glu421) formed by juxtaposition of the J′ and K″ helices,
respectively (Fig. 1) [54]. In a similar manner anti-CYP2E1 anti-
bodies associated with CHC target an area comprised between
Lys324 and Glu346 at the juxtaposition of the J and J′ helices (Fig. 1)
that partially overlaps with one the epitopes recognized by anti-
bodies from ALD and halothane-induced hepatitis subjects [55]. This
suggest the possible presence of antigenic hot-spots of CYP2E1 mo-
lecular structure. In the same vein, sequence alignments demonstrate
that the CYP2E1324–346 epitope is has an amino acid sequence close
to the peptides CYP2D6316–327 and CYP2D6321–379 that are among the
most frequent targets of anti-CYP2D6 LKM-1 antibodies [17,56]. In-
terestingly, the J, K and L helices are also binding sites of anti-CYP2C9
and anti-CYP3A4 conformational antibodies associated with tienilic
acid-induced autoimmune hepatitis and hypersensitivity reactions to
aromatic anti-convulsing drugs, respectively [7,9]. These analogies
are not surprising considering that CYP2 and CYP3 families have a
high sequence homology and indicate that CYP auto-antigens are
preferentially located in deﬁned and rather conserved structures of
the molecule.formational epitopes recognized by anti-CYP2E1 IgG present in the sera of patients
tis C (panel C). (Panels A, C) The area formed by the juxtaposition of J′ and K″ helices
itope in the G helix comprised between Lys324 and Lys251 is shown in orange. (For
he web version of this article.)
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autoantibodies
As mentioned above, a small fraction of CYP2E1 is located on
the outer layer of hepatocyte the plasma membranes [26,27].
Structural simulations based on CYP2E1 interaction with mem-
brane lipids indicate that the conformational epitopes identiﬁed in
G helix and in the area comprising the J–L helices are located on
the outer portion of the molecule and are well accessible to the
antibody binding [54]. In line with this, we have observed that
anti-CYP2E1 auto-antibodies present in CHC [49] as well as those
associated with ALD or halothane-induced hepatitis [29] bind to
hepatocytes by recognizing plasma membrane CYP2E1. Thus, as in
the case of LKM-1 antibodies [19], the binding of anti-CYP2E1 IgG
to conformational epitopes on G and J–L helices has the capability
to trigger antibody-mediated cytotoxicity, thus justifying the
clinical association between anti-CYP2E1 reactivity and the se-
verity of liver injury. Supporting this view we have observed that
HER-modiﬁed CYP2E1 can mediate cytotoxic reactions by anti-
HER antibodies from ALD patients [38]. This does not exclude that,
as observed for anti-CYP2D6 auto-reactivity [20,21], T cell-medi-
ated responses against CYP2E1 might also be involved in causing
hepatocyte damage.Mechanisms in the breaking of immune-tolerance toward
CYP2E1
So far, the mechanisms leading to the breaking of self-tolerance
toward hepatic CYP2E1 are still incompletely characterized. The
liver is recognized to have unique immunological properties that
modulate systemic tolerance to antigens from the portal circula-
tion [57,58]. Under physiological conditions, Kupffer cells respond
to low concentrations of bacterial products by producing inter-
leukin-10 (IL-10) and low levels of pro-inﬂammatory mediators
(TNF-α, ROS and prostanoids) that down-modulate the antigen
presentation by dendritic and endothelial cells, thus suppressing
T-cell activation [58]. Such an effect is lost following liver injury
because of macrophage and dendritic cell (DC) activation in re-
sponse to damage associated molecular patterns (PAMPs) [57].
Classically, B-cell activation, differentiation and proliferation occur
in secondary lymphoid organs or in so-called “ectopic” germinal
centers of non-lymphoid organs. In injured livers intra-portal
lymphoid follicles acquire the features of active germinal centers
[57], making possible the presentation of hepatocyte-derived an-
tigens to B- and CD4þ T-lymphocytes as well as B-cell maturation
to antibody producing plasma cells. Moreover, DCs can also cross-
prime naïve CD8þ T-lymphocytes promoting cell-mediated
responses. Beside DC, antigen presentation might also involve
hepatic stellate cells [59] and possibly hepatocytes themselves, as
pro-inﬂammatory cytokines have been shown to induce the
hepatocyte expression of class II major histocompatibility complex
(MHC) and co-stimulatory CD80 (B7.1) molecules [60]. Although
during chronic liver injury CYP released from damaged hepato-
cytes might be a trigger for the breaking of self-tolerance, it should
be noted that anti-CYP self-reactivity associated to CHC, alcohol
abuse or adverse drug reactions is highly speciﬁc to individual
CYPs [7–10] and there is no cross-reactivity between anti-CYP2E1
and anti-CYP2D6 antibodies [54,55] in HCV-infected patients. This
indicates that additional and more speciﬁc mechanisms are likely
involved.
Early studies have postulated that during drug-induced hepa-
titis the binding of reactive metabolites to CYPs would be able to
promote immune responses against the drug-derived epitope
(s) favouring at the same time the activation of normally quiescent
auto-reactive lymphocytes recognizing native CYP molecules [61].Although such a hypothesis has not been deﬁnitively proved, it is
interesting to note that antibodies against CYP2E1 modiﬁed by the
binding of drug-derived metabolites often accompany the pre-
sence of anti-CYP2E1 auto-antibodies in halothane and isoniazid
idiosyncratic hepatitis [29,34] as well as in ALD [40]. In particular,
we have observed that ALD patients with anti-HER antibodies
have a 4 fold increased risk of developing anti-CYP2E1 auto-re-
activity as compared to patients without anti-HER IgG [40], in-
dicating that CYP2E1 structural modiﬁcations induced by HER are
critical for the breaking of self-tolerance. This is consistent with
the observation that small molecular difference are needed for the
breaking of T-cells tolerance versus CYP2D6 in mice developing
autoimmune hepatitis following infection with adenovirus
expressing human CYP2D6 [62]. Furthermore, structural mod-
iﬁcations of the pyruvate dehydrogenase complex consequent to
biotinylation are required for the development auto-reactive
B-cells and T-cells in an experimental model of biliary cirrhosis
[63]. In this contest, genetic polymorphisms that inﬂuence the
capacity of CYPs to generate reactive metabolites or that affect
drug metabolite detoxiﬁcation by phase II enzymes might likely
inﬂuence inter-individual variability in the development of anti-
CYP auto-reactivity [64]. However, in spite many genetic poly-
morphisms have been detected in CYP2E1 [65], at the moment no
data has implicated their inﬂuence in the susceptibility to auto-
immune responses.
Current researches on the mechanisms by which HCV infection
promotes the onset of autoimmune reactions have focused on the
peculiar ability of HCV to cause molecular mimicry [1,14].
Molecular mimicry deﬁnes the possibility that antigens from
microorganisms can activate T-lymphocytes cross-reacting with
self-antigens that share similar linear or conformational structures
[66]. By now mimicry mechanisms involving viral proteins are
recognized to play a key role in the pathogenesis of several human
autoimmune diseases [66]. In the case of anti-CYP auto-reactivity,
mimicry between HCV proteins E1, NS3, NS5a and NS5b and
CYP2D6 accounts for the development of LKM-1 auto-antibodies
[15,18,67] and T-cells antigens in CYP2D6, CYP2A6 and CYP2A7
[13,68]. Moreover, cross-reactivity between CYP2D6 and Cytome-
galovirus and Herpes Simplex virus proteins has also been re-
ported [16,18]. We have observed that the conformational epitopes
in CYP2E1324–346 that are recognized by CHC-associated
anti-CYP2E1 IgG have good sequence homology with two short
peptides (NS5b438–449 and NS5b456–465) well conserved in NS5b
RNA-dependent-DNA polymerase of most of HCV genotypes [55].
Furthermore, molecular imaging shows similarities in the tri-di-
mensional structure of these peptides and those of the epitopes in
CYP2E1 molecule [55]. Accordingly, recombinant NS5b438–449 and
NS5b456–465 peptides cross-react with CHC sera containing con-
formational anti-CYP2E1 IgG, while mice immunized with either
the two viral peptides develop antibodies targeting human
CYP2E1 [55]. Altogether, these data indicate molecular mimicry
with HCV-NS5b a trigger for the development of auto-reactivity
toward CYP2E1 in CHC. This might explain why the prevalence of
anti-CYP2E1 auto-antibodies is unrelated to alcohol consumptions
despite alcohol abuse is itself a trigger of autoimmune responses.
More in general, mimicry mechanisms can be seen as a common
mechanism in the breaking of self-tolerance toward CYPs in HCV
infected patients.
Although CYP2E1 modiﬁcations by reactive metabolites and
molecular mimicry can facilitate the selection of B- and T-cells
with speciﬁcity toward CYP2E1 epitopes, additional factors may
inﬂuence the large inter-individual variability that characterizes
the presence of anti-CYP2E1 auto-reactivity in liver diseases. In
this respect, the activity of regulatory T (Treg) cells is known to
play an important role in the maintenance of immune homeostasis
and in the prevention of autoimmune diseases [69,70]. In the liver,
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tributor in the development of autoimmune hepatitis [71]. Among
the mechanisms by which Tregs regulate immune functions a key
role is played by cytotoxic T lymphocyte associated antigen-4
(CTLA-4) [72]. CTLA-4 is membrane protein that act as an in-
hibitory signal to T cells by competing with CD28 for interacting
with CD80 (B7.1) and CD86 (B7.2) [73,74]. By this mechanism
CTLA-4 interferes with important co-stimulatory signals essential
for T-cell activation [73,74]. The immune-suppressor function of
CTLA-4 is conﬁrmed by observations that CD4þ and CD8þ T- and
of B-cell clones rapidly expand in CTLA-4 knockout mice leading to
lethal auto-reactive diseases [75]. In vitro data have shown that a
human genetic polymorphisms involving a A-G base exchange at
position 49 in exon 1 of the CTLA-4 gene is associated with a di-
minution of the normal inhibitory inﬂuence on T cell responses
[73,74]. Moreover, primary biliary cirrhosis, type I auto-immune
hepatitis, Graves' disease and type 1 diabetes mellitus have all
been linked to the presence of such CTLA-4 polymorphisms
[73,74]. We have observed that ALD patients have an increased
prevalence CTLA-4 49 A/G substitution than healthy subjects.
Moreover, in heavy drinkers the presence of the CTLA-4G allele
increases by about four folds the risk of developing anti-CYP2E1
IgG, without inﬂuencing the prevalence of antibodies towards
HER-antigens [40]. Interestingly, ALD patients having the combi-
nation both anti-HER IgG and the mutant CTLA-4 G allele have 23-
fold higher risk of anti-CYP2E1 auto-reactivity than the subjects
negative for both these factors [40]. Although ALD patients have
also an increased prevalence of genetic polymorphisms (627C-A
and 1.117G-A) affecting IL-10 secretion by Tregs and macro-
phages, this does not inﬂuence the prevalence of anti-CYP2E1 IgG
[40]. Thus, the antigenic stimulation by HER-modiﬁed CYP2E1
combined with an impaired control of T cell proliferation due to
CTLA-4 mutation appears to speciﬁcally increase the probability to
develop anti-CYP2E1 auto-reactivity. Altogether, these observa-
tions indicate that the breaking of self-tolerance toward CYPs is a
multi-factorial event likely requiring structural modiﬁcations of
the target molecule or molecular mimicry along with genetic or
acquired interferences with the mechanisms controlling the
homeostasis of the immune system.Conclusions
Autoimmune reactions involving CYP2E1 play an important
role in idiosyncratic liver injury induced by halogenated hydro-
carbons and isoniazid, but are also detectable in about one third of
the patients with advanced ALD or CHC. In these latter the pre-
sence of anti-CYP2E1 auto-antibodies is an independent predictor
for extensive necro-inﬂammation and ﬁbrosis. However, more
studies are needed to better characterize the impact of anti-
CYP2E1 autoimmunity in liver diseases particularly in relation to
type II autoimmune hepatitis which is characterized by anti-CYP
auto-reactivity [76] and nonalcoholic steatohepatitis (NASH), as in
this later, insulin resistance associated to obesity stimulates he-
patic CYP2E1 induction [77,78].Conﬂict of interest
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